Skip to main content

Safety and Tolerability in Healthy Volunteers

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
SSS39Phase 11 trial
Active Trials
NCT07057726Enrolling By Invitation48Est. Oct 2025
Neuraly
NeuralyMD - Gaithersburg
1 program
NLY01PHASE_11 trial
Active Trials
NCT03672604Completed96Est. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sunshine BiopharmaSSS39
NeuralyNLY01

Clinical Trials (2)

Total enrollment: 144 patients across 2 trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

Start: Oct 2024Est. completion: Oct 202548 patients
Phase 1Enrolling By Invitation

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

Start: Sep 2018Est. completion: Jul 201996 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.